Protagonist Therapeutics Inc. (PTGX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XBER 
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to earnings of $3.26 per share a year ago.
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025 Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CALIFORNIA / ACCESS Newswire / May 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "Protagonist is off to a very strong 2025 with multiple transformational events in the first quarter for our two late-stage partnered assets, rusfertide and icotrokinra which are progressing to NDA filings by year end," said Dinesh V.
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the "Grant Date"), it issued an equity inducement award to a new employee upon his commencement of employment with the Company in accordance with the terms of his employment offer letter. The award was granted under the Company's Amended and Restated 2018 Inducement Plan, which was adopted on May 29, 2018, and amended on February 18, 2020 and February 15, 2022.
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced its inclusion in Fast Company's prestigious annual list of the World's Most Innovative Companies for 2025. Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and transformative technologies.
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk.
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Overlooked Stock: PTGX
Protagonist Therapeutics (PTGX) rallied 45% after its latest drug trial to treat people with active ulcerative colitis saw success. George Tsilis says there's more positive catalysts behind the stock, particularly its cash pile.
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study. The post Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out appeared first on Investor's Business Daily.
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC).
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first.
